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Perrault Syndrome Is Caused by Recessive
Mutations in CLPP, Encoding a Mitochondrial
ATP-Dependent Chambered Protease
Emma M. Jenkinson,1,14 Atteeq U. Rehman,2,14 Tom Walsh,3,14 Jill Clayton-Smith,1 Kwanghyuk Lee,4
Robert J. Morell,2 Meghan C. Drummond,2 Shaheen N. Khan,5 Muhammad Asif Naeem,5 Bushra Rauf,5
Neil Billington,6 Julie M. Schultz,2 Jill E. Urquhart,1 Ming K. Lee,3 Andrew Berry,7 Neil A. Hanley,7
Sarju Mehta,8 Deirdre Cilliers,9 Peter E. Clayton,10 Helen Kingston,1 Miriam J. Smith,1
Thomas T. Warner,11 University of Washington Center for Mendelian Genomics, Graeme C. Black,1
Dorothy Trump,1 Julian R.E. Davis,7 Wasim Ahmad,12 Suzanne M. Leal,4 Sheikh Riazuddin,5,13
Mary-Claire King,3 Thomas B. Friedman,2,* and William G. Newman1,*
Perrault syndrome is a genetically and clinically heterogeneous autosomal-recessive condition characterized by sensorineural hearing
loss and ovarian failure. By a combination of linkage analysis, homozygosity mapping, and exome sequencing in three families, we
identified mutations in CLPP as the likely cause of this phenotype. In each family, affected individuals were homozygous for a different
pathogenic CLPP allele: c.433A>C (p.Thr145Pro), c.440G>C (p.Cys147Ser), or an experimentally demonstrated splice-donor-site
mutation, c.270þ4A>G. CLPP, a component of a mitochondrial ATP-dependent proteolytic complex, is a highly conserved endopepti-
dase encoded by CLPP and forms an element of the evolutionarily ancient mitochondrial unfolded-protein response (UPRmt) stress
signaling pathway. Crystal-structure modeling suggests that both substitutions would alter the structure of the CLPP barrel chamber
that captures unfolded proteins and exposes them to proteolysis. Together with the previous identification of mutations in HARS2,
encoding mitochondrial histidyl-tRNA synthetase, mutations in CLPP expose dysfunction of mitochondrial protein homeostasis as
a cause of Perrault syndrome.More than 400 syndromic forms of deafness have been
defined.1 The specific genes causing some of these condi-
tions have been identified, providing important insights
into the molecular pathways and structures impaired in
sensorineural hearing loss (SNHL).2 Perrault syndrome
(MIM 233400) is an autosomal-recessive disorder charac-
terized by SNHL and premature ovarian failure (POF)
secondary to ovarian dysgenesis.3 It is clinically and genet-
ically heterogeneous.4,5 A spectrum of additional clinical
features, including cerebellar ataxia, learning disability,
and peripheral neuropathy, have been described in some
affected individuals.5–7
Mutations in two genes, HSD17B4 (MIM 601860), en-
coding D-bifunctional protein (DBP), and HARS2 (MIM
600783), encoding mitochondrial histidyl-tRNA synthe-
tase, have been identified as underlying causes of Perrault
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Figure 1. Pedigrees of the Three Fami-
lies—PDF1, PKDF291, and DEM4395—
Affected by Homozygous CLPP Mutations
Numbers are assigned only to individuals
whose DNA was available for this study.
Arrowheads denote individuals whose
genomic DNA was subjected to exome
sequencing. Parents of the six siblings in
family PKDF291 have the same great-great
grandparents.10 A double horizontal line
denotes a consanguineous union. Family
PDF1 was ascertained because of profound
hearing loss in three sisters with subse-
quent POF. Families PKDF291 and
DEM4395 first came to attention because
of profound hearing loss in the affected
family members. In family PKDF291, POF
was revealed by subsequent evaluation of
the affected sisters. In family DEM4395,
no hormonal evaluation was possible.level [dBHL] at all test frequencies [Figure S1, available on-
line]). The youngest affected sibling (II-6) was evaluated for
delayed puberty at 15 years of age. Pelvic ultrasonography
revealed streak ovaries and a hormone profile consistent
with hypergonadotropic hypogonadism (Table 1). Subse-
quent hormone profiles in her elder siblings (II-2 and
II-4) with hearing loss revealed elevated gonadotropin
levels consistent with incipient POF. The menstrual cycles
of both sisters had become erratic with infrequent menses.
Of note, the oldest sister (II-2) had given birth to two
healthy sons, demonstrating significant prior ovarian
reserve, despite the fact that only one of her ovaries was
detectable on pelvic ultrasonography when she was 22
years old. All three affected siblings were prescribed
estrogen replacement therapy for the prevention of osteo-
porosis. In addition to having SNHL and ovarian failure,
the three affected siblings have epilepsy, short stature
(less than the third percentile), microcephaly (less than
the third percentile), and moderate learning difficulties.
Phenotypic features also include truncal and cerebellar
ataxia with signs of lower-limb spasticity. An MRI brain
scan of the eldest affected sibling (II-2) showed abnormally
high signal intensity in the deep white matter and cortico-
spinal tract (data not shown).
Genome-wide homozygosity mapping of the three
affected sisters and an unaffected sibling from family
PDF1 was performed with an Affymetrix Human Array
6.0, as previously described,11 and was analyzed with
AutoSNPa software.12 The only >1 Mb homozygosity
region shared by the three affected sisters, but not by their
unaffected sister, was chr19: 5,765,869–16,392,163 (refer-
ence human genome sequence GRCh37, UCSC hg19),
flanked by SNPs rs4366824 and rs3852916, in the region
19p13.3–p13.11 (Figure S2). This 10.63 Mb region includes
approximately 300 annotated genes.
A second large unrelated consanguineous Pakistani
family, PKDF291 (Figure 1 of Rehman et al.10), affected
by severe to profound congenital SNHL was also found to
display linkage to chromosomal region 19p13. Linkage
analysis, which was performed with 388 microsatellite606 The American Journal of Human Genetics 92, 605–613, April 4, 2markers, defined a 4.17 Mb SNHL locus with a maximum
multipoint LOD score of 3.35 for the marker D19S391,
located in this region.10 This locus, designated DFNB81,
encompasses 104 genes. GIPC3 (MIM 608792), which is
located adjacent to the DFNB81 interval, was Sanger
sequenced, and no mutations in the affected individuals
of family PKD291 were identified.10 Further evaluation of
the phenotypic features revealed primary amenorrhea
and hormone profiles indicative of hypergonadotropic hy-
pogonadism in all four affected female siblings (Table 1).
The three elder affected female siblings (PKDF291 II-3, II-
4, and II-5) each had a rudimentary uterus and small
ovaries on pelvic ultrasonography, whereas the youngest
affected sibling (II-2) had a small uterus and normal-sized
ovaries at 15 years of age. The unaffected sibling (II-6)
had normal imaging of her uterus and ovaries. There was
no evidence of learning disability, microcephaly, short
stature, epilepsy, or neurological deficit in this family.
In a third consanguineous Pakistani family, DEM4395
(Figure 1), a 25-year-old male (IV-3; Figure S1) and two of
his sisters were found to have profound congenital SNHL
(>90 dBHL at 250–8,000 Hz). Both affected female siblings,
IV-4 and IV-5, were reported to have normal menstrual
cycles at ages 28 and 22 years, respectively, although
formal evaluation of hormone profiles was not possible.
No additional medical problems were self-reported by
this family.
DNA samples from five individuals in family DEM4395
were genotyped at the Center for Inherited Disease
Research with the use of the Illumina Linkage Panel 12.
In chromosomal region 19p13, a 15.64 Mb homozygous
locus flanked by 19pter and rs1273522 and with
a maximum multipoint LOD score of 2.53 was observed.
GIPC3 was included in the region of homozygosity in
family DEM4395, and Sanger sequencing of GIPC3 coding
exons revealed no mutations.
Exome sequencing was undertaken for affected individ-
uals II-4 from family PDF1, II-3 from family PKDF291, and
IV-3 from family DEM4395 (Table S1). For families PDF1
and DEM4395, exome sequencing was independently013
Table 1. Hormone Profiles of Individuals from Families PDF1 and PKDF291
Family Individual (Age at Assessment) FSH (Normal Range) LH (Normal Range) Estradiol (Normal Range)
PDF1 II-2 (22 years) 41.5 (2–14 IU/l) 64.6 (2–14 IU/l) 777 (70–1,480 pmol/l)
II-4 (21 years) 24.6 (2–14 IU/l) 17.7 (2–14 IU/l) 281 (70–1,480 pmol/l)
II-6 (15 years) 45 (2–14 IU/l) 104 (2–14 IU/l) 89 (70–1,480 pmol/l)
PKDF291 II-2 (15 years) 111 (2.8–11.1 IU/l) 29.4 (0–11.6 IU/l) <20 (ND–160 pg/ml)
II-3 (20 years) 104 (2.8–11.1 IU/l) 49.8 (0–11.6 IU/l) <20 (ND–160 pg/ml)
II-4 (23 years) 81 (2.8–11.1 IU/l) 26 (0–11.6 IU/l) <20 (ND–160 pg/ml)
II-5 (25 years) 101 (2.8–11.1 IU/l) 31 (0–11.6 IU/l) <20 (ND–160 pg/ml)
II-6 (18 years) (unaffected) 3.28 (1.2–9 IU/l) 4.85 (0–14.7 IU/l) 185 (27–246 pg/ml)
The following abbreviations are used: FSH, follicle stimulating hormone; LH, luteinizing hormone; and ND, not determined.carried out in the King lab and in the Department of
Genome Sciences sequencing core, respectively, at the
University of Washington with the use of previously re-
ported methods,13,14 whereas family PKDF291 was exome
sequenced on an Applied Biosystems SOLiD 5500 platform
in the National Institute on Deafness and Other Commu-
nication Disorders sequencing core.15 All high-quality
reads were mapped to the reference human genome
sequence (GRCh37, UCSC hg19).
The mapped loci in chromosomal region 19p13 overlap-
ped in the three families, and homozygous variants absent
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Variant Server (ESP6500) were identified
in only one gene, CLPP (MIM 601119), in the three fami-
lies. The three variants were confirmed by PCR amplifica-
tion from genomic DNA and subsequent Sanger sequence
analysis (Figure 2). In family PDF1, a missense variant,
c.433A>C (RefSeq accession number NM_006012)
(p.Thr145Pro [RefSeq NP_006003]), was identified at
chr19: 6,364,528. In family PKDF291, another missense
variant, c.440G>C (p.Cys147Ser), was identified at chr19:
6,364,535. Both variants cosegregated with the phenotype
and were absent in 193 (for c.433A>C [p.Thr145Pro]) and
483 (for c.440G>C [p.Cys147Ser]) ethnically matched
controls. Evidence of pathogenicity was supported by
the high conservation of both substituted residues
(Figure 2C) and structural defects predicted from the anal-
ysis of the primary amino acid sequence. SIFT, Muta-
tionTaster, and PolyPhen-2 predicted both substitutions
to be damaging. Sanger DNA sequencing of all coding
exons of CLPP in 20 other Perrault-syndrome-affected
families from the University of Washington8,9 and Univer-
sity of Manchester5 cohorts did not reveal other families
with mutations.
A homozygous CLPP variant, c.270þ4A>G at chr19:
6,361,955, was identified in the three affected individuals
of family DEM4395. This variant was absent in 386 ethni-
cally matched controls. MutationTaster predicted it to
abolish the splice donor site of CLPP exon 2. Because
CLPP mRNA could not be amplified from saliva samples
of either affected individuals or controls (Oragene RNA,The AmDNAGenotek), the effect ofCLPP c.270þ4A>G on splicing
was tested experimentally in COS-7 cells (Figures 2D and
2E and Table S2). Splicing assays compared the wild-type
allele, the CLPP c.270þ4A>G mutant allele of family
DEM4395, and CLPP c.270þ1G>A, a donor-site control
mutation expected to ablate exon 2 splicing to exon 3.
For the wild-type sequence, 62% (23/37) of cloned tran-
scripts had canonical splicing of exons 2 and 3, 30% (11/
37) of clones retained intron 2, and 8% (3/37) of clones
had other aberrant transcripts. For control CLPP
c.270þ1G>A, all (39/39) clones retained intron 2. The
CLPP c.270þ4A>G allele was evaluated in four experi-
ments. From all four experiments combined, 84% (41/49)
of clones from CLPP c.270þ4A>G transcripts retained
intron 2, 4% (2/49) of clones spliced at a cryptic donor
site (CLPP c.255_256G>T), 10% (5/49) of clones had aber-
rant splicing that excluded either exon 2 or exon 3 and
were most likely artifacts, and 2% (1/49) of clones had
wild-type splicing. Wild-type splicing was independently
confirmed in additional experiments. Nested PCR splicing
products (of approximately 300–350 bp) detected on an
agarose gel indicated possible wild-type splicing for the
c.270þ4A>G allele, and we confirmed this by gel purifica-
tion, cloning, and Sanger sequencing (Figure 2E). Intron 2
includes stop codons in all reading frames. If the reading
frame of exon 2 is retained, then translation termination
occurs 38 codons after wild-type codon 90. We conclude
from these data that, as predicted, the c.270þ4A>G
mutant allele of CLPP does not fully ablate donor splice-
site function but rather weakens it.
Human CLPP (EC 3.4.21.92; UniProtKB Q16740) is the
caseinolytic peptidase, proteolytic subunit homolog of
E. coli ClpP. The protein is highly conserved at the primary
amino acid sequence level through the quaternary struc-
ture level among all prokaryotes and eukaryotes.16–19
CLPP is an endopeptidase component of a mitochondrial
ATP-dependent proteolytic machine.16 Degradation of
proteins by CLPP occurs when an unfolded polypeptide
chain is translocated into its interior chamber. The active
unit of CLPP is a barrel-shaped tetradecamer, which results
from the face-to-face association of two heptamericerican Journal of Human Genetics 92, 605–613, April 4, 2013 607
Figure 2. Identification of CLPP Muta-
tions in Families PDF1, PKDF291, and
DEM4395
(A) Chromatograms obtained from a wild-
type control and homozygous affected
individuals from three families. Mutations
are highlighted in gray.
(B) Gene structure ofCLPP and the location
of the three mutations identified in this
study. Thin bars represent 50 and 30 UTRs,
and thick bars represent exons. The hori-
zontal lines joining exons represent in-
tronic sequence.
(C) A ClustalW alignment of CLPP ortho-
logs in five animal species from human to
Drosophila shows conservation of residues
145 and 147, which correspond to the
substitutions identified in families PDF1
and PKDF291, respectively.
(D) Schematic presentation of the exon-
splicing-assay vector used in COS-7 cells
for the evaluation of the predicted splice-
site mutation. CLPP exon 2, either with
a wild-type donor site or a mutant donor
splice site (c.270þ4A>G or control
c.270þ1G>A), was cloned into the pSPL3
expression vector (gray). The CLPP
sequence also included intron 2, exon 3,
and 660 bp of flanking intronic sequences
(black). Horizontal arrows indicate loca-
tions of vector-specific primers used for
PCR amplification of cDNA containing
the CLPP sequence.
(E) Splicing-assay products were separated
by size on a 2% agarose gel for the wild-
type allele, the DEM4395 c.270þ4A>G
mutant allele, and the c.270þ1G>A
control mutation. The 851 bp band is
from CLPP transcripts that include intron
2. Sequencing of the two ~300–350 bp
gel-purified bands demonstrates that the
c.270þ4A>G mutant allele results in
some wild-type splicing between CLPP
exons 2 and 3. Additional splicing assay
data in Table S2 support this conclusion.rings.18–20 This barrel creates the large central cavity in
which proteolysis occurs. Substrate peptides enter the
chamber via an axial pore and are exposed to 14 active sites
within the barrel. In order to allow proteolysis of larger
substrates, the CLPP tetradecamer binds the hexameric
protein CLPX (caseinolytic peptidase X). CLPX is an
AAAþ protein family member (i.e., an ATPase associated
with a wide variety of cellular activities). CLPX recognizes
and unfolds specific protein substrates. The newly
unfolded peptides are extruded through the central
pore of its hexameric ring into the CLPP proteolytic
chamber.21
Multiple crystal structures and electron-microscopy
density maps have been determined for CLPP. These struc-
tures can be used for predicting the consequences of amino
acid substitutions in the protein. Crystal structures include
a 2.1-A˚ structure of human CLPP and several bacterial ClpP
orthologs.18,19,22–31 Each CLPP monomer consists of a
globular ‘‘head’’ domain and an extended ‘‘handle’’
domain (Figure 3A). The catalytic triad, Ser153 (97)-608 The American Journal of Human Genetics 92, 605–613, April 4, 2His178 (122)-Asp227 (171), is formed in the cleft between
these two domains. The parenthetical numbers are the resi-
dues after removal of 56 amino acids composing the
N-terminal mitochondrial targeting sequence (MTS); the
MTS is cleaved after translocation of CLPP to the mito-
chondrion, yielding the mature polypeptide. The head
region, in which the missense substitutions of families
PDF1 and PKDF291 are found, consists of two perpendic-
ular b sheets associated with six a helices (Figure 3B). The
two affected residues lie within the b-3 strand of the first
b sheet and contribute to backbone hydrogen bonding of
the b sheet. The side chain of residue Thr145 (89) can
also form a hydrogen bond with residue Leu159 (103) of
the a4 helix, which contains the catalytic residue
Ser153 (97). Substitution of Thr145 (89) with proline
(p.Thr145Pro) removes the possibility of hydrogen-bond
formation to Leu159 (103) and Met166 (110). Indeed,
the b sheet properties of proline are likely to cause signifi-
cant disruption of the structure in this region. The conse-
quences of the replacement of Cys147 (91) with serine013
Figure 3. Location of Substitutions with-
in the Crystal Structure of Human CLPP
(A and B) Surface representations show
the side (A) and top (B) views of a single
heptameric ring of CLPP subunits (Protein
Data Bank 1tg6). The ribbon representa-
tion shows a single monomer within the
ring in each case. The b strand affected
by the two substitutions is highlighted
in red.
(B) A ribbon representation shows the
position of substitutions at the base of
the CLPP hydrophobic pocket. Substitu-
tions are shown in red, and adjacent
hydrophobic residues known to be impor-
tant in CLPX binding are shown in green.
The catalytic triad is highlighted in orange.
The single-letter codes for amino acid
residues and numbers shown here are
after cleavage of the mitochondrial target-
ing sequence (MTS), which removes the
N-terminal 56 residues. Hence, the residue
labeled T89 is equivalent to T145 in the
unprocessed polypeptide. This is for
consistency with studies relating to the
structure of CLPP. The poorly resolved
N-terminal region (residues 1–17) was
omitted for clarity.(p.Cys147Ser) are less clear, but one result would be reduc-
tion in hydrophobicity of the side chain.
The affected b3 strand lies at the base of a deep hydro-
phobic cleft, which is important in mediating the interac-
tion with the CLPX ATPase in the CLPXP holoenzyme.22,26
The two residues, Trp146 (90) and Val148 (92), which
neighbor the Perrault syndrome substitutions, have been
shown to play a role in binding to the macrolactone core
of acyldepsipeptides ADEP1 and ADEP2 in B. subtilis.29
ADEPs are activators of bacterial ClpP, and the interaction
between ClpP and ADEPs has been proposed to mimic the
interaction between ClpP and the Ile-Gly-Phe/Lys loops of
the Clp ATPases.28 A change in the position of key residues
within the hydrophobic pocket might therefore affect
the docking of CLPX onto CLPP, thus reducing the ability
of the CLPXP complex to perform targeted degradation
of substrates. The p.Thr145Pro substitution is expected
to cause a more dramatic structural change than is
p.Ser147Cys, and this might explain the more severe
phenotype of this family.
CLPP localization was evaluated specifically for human
and mouse ovaries and for mouse organ of Corti (Figure 4).
In the initial descriptions of Perrault syndrome, ovarian
dysgenesis resulting in primary ovarian failure is
described.3 Therefore, human fetal ovarian tissue was eval-
uated for accumulation of CLPP during follicular develop-
ment. At approximately 18 weeks of gestation (20 mm foot
length), CLPP localized to germ cells of developing tissue.
CLPP was not detected in the stromal layers. Staining
was particularly evident around the nuclei of germ cells,
consistent with the localization of mitochondria
(Figure 4A).32 In mice, Clpp was widely expressed in adultThe Amand fetal tissues (Figure S3). In the adult mouse ovary,
CLPP was localized in granulosa cells and oocytes (Figures
4C and 4D), whereas in the immature organ of Corti at
postnatal day 3 (Figures 4E and 4F), CLPP localized
predominantly in supporting cells. At this age, a weak
CLPP signal was detected in adjacent sensory hair cells
despite their abundance of mitochondria, as evidenced
by strong cytochrome c signal by immunolocalization
(Figure 4F) and previously published transmission-elec-
tron-microscopy images.33 The functional relevance of
apparently restricted localization of CLPP mainly in germ
cells of the developing ovary, granulosa cells and oocytes
of the mature ovary, and supporting cells of the organ of
Corti is not known. Perhaps higher levels of CLPP in these
cell types might indicate a specific need for proteolysis of
particular unfolded or misfolded proteins to preclude
damage.
Our data strongly suggest that biallelic recessive muta-
tions in CLPP result in Perrault syndrome. The phenotypic
variability within and between members of the three
families affected by CLPP mutations is striking. In family
PDF1, in addition to comprising POF and SNHL, the
phenotype includes progressive spastic paraplegia, growth
restriction, learning disability, and nonspecific white-
matter changes on brain imaging. In contrast, in family
PKDF291, the phenotype includes only POF and SNHL.
In family DEM4395, all affected individuals have SNHL,
but formal evaluation of hormone levels could not be
carried out in affected females.
The severe phenotype of family PDF1 might be due to
their CLPP allele and/or to additional homozygous
missense mutations. In the critical autozygous region inerican Journal of Human Genetics 92, 605–613, April 4, 2013 609
Figure 4. Immunolocalization of CLPP in
Human Fetal Ovary, Adult Mouse Ovary,
and P3 Mouse Organ of Corti
(A) Immunodetection (brown staining) of
CLPP in germ cells of human fetal ovary
(approximately 18 weeks of gestation;
20 mm foot length). Staining was particu-
larly evident around nuclei of germ cells,
consistent with the localization of mito-
chondria. Staining was not evident in the
stromal layers. Human fetal tissue was
collected with ethical approval under the
Codes of Practice of the UK Human Tissue
Authority and staged by foot length. For
bright-field studies, endogenous peroxidase
was quenched by incubation with 30%
hydrogen peroxide and antigen retrieval
was undertaken by heating at 95C for
5 minutes in sodium citrate pH 6. Rabbit
CLPP antibody (Sigma-Aldrich HPA010649)
was used as the primary antibody, and
unconjugated goat anti-rabbit IgG (Vector
Labs AI-1000) was used as the secondary
antibody. A system of streptavidin, horse-
radish peroxidase, and diaminobenzidine
(Vector Labs) was used for generating
a brown signal. Scale bars represent 50 mm.
(B) Immunoblot analysis for the validation
of the rabbit monoclonal CLPP antibody
(AbCam ab124822). When used at a
1:2,000 dilution in ECL Prime blocking
reagent (GE RPN418V), this rabbit mono-
clonal antibody recognizes a predicted
26 kDa CLPP protein in 4 mg of a postnatal
day (P) 25 mouse ovary lysate, 4 mg of a P3
mouse cochlea lysate, and 0.5 mg of COS-7
cell lysate. COS-7 cells were also transfected
with pAcGFP-N2-CLPP and expressed
GFP-tagged CLPP proteins of 57 kDa and
51 kDa. The latter protein presumably lacks
the predicted 6 kDa MTS. Endogenous
26 kDa CLPP was also detected in these
COS-7 cells.
(C and D) Immunohistochemistry of an
adult mouse ovary reveals CLPP expression
in granulosa cells (G) and oocytes (O).
CLPP staining is absent in the zona pellucida
(ZP) and theca (T). Fixed-frozen sections
(Zyagen MF-406) were labeled with a rabbit
monoclonal CLPP antibody as described
below and counterstained with a 1:100 dilution of phalloidin-Atto 390 (Sigma 50556). Scale bars represent 30 mm.
(E) An optical section of a P3mouse organ of Corti at the level of the cuticular plate reveals that CLPP (green) ismore abundant in Deiter’s
cells (DCs), inner pillar cells (PCs), and Hensen’s cells (HCs) than in inner sulcus cells (ISCs), inner hair cells (IHCs), and outer hair cells
(OHCs). CLPP colocalized with the mitochondrial protein cytochrome c (red). After dissection from the temporal bone, cochleae were
fixed in 4% paraformaldehyde. Tissues were finely dissected, permeabilized in PBS containing 0.5% Triton X-100, and incubated over-
night in 1:100 dilutions of rabbit CLPP antibody and mouse cytochrome c antibody (BD Biosciences 556433) in 5% goat serum and 2%
BSA blocking solution. Primary antibodies were detected with 1:400 dilutions of Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen
21206) and Alexa Fluor 568 goat anti-mouse IgG (Invitrogen 11004) in blocking solution. Scale bars represent 10 mm.19p13, two additional variants in PCP2 (MIM 602454) and
GTF2F1 (MIM 189968) were identified in family PDF1. The
c.392C>G (RefSeq NM_174895) (p.Pro131Arg [RefSeq
NP_777555]) mutation in PCP2 was predicted to be
damaging by MutationTaster, PolyPhen-2, and SIFT. The
other variant, c.1328G>T (RefSeq NM_002096)
(p.Gly443Val [RefSeq NP_002087]) in GTF2F1, was pre-
dicted to be damaging by MutationTaster and PolyPhen-
2 but ‘‘tolerated’’ by SIFT. Both variants were absent in610 The American Journal of Human Genetics 92, 605–613, April 4, 2a panel of ethnically matched controls (n ¼ 193) and
affect residues conserved in mouse (PCP2) and zebrafish
(GTF2F1). Variants in the protein-coding regions of these
genes were not present in the affected individuals from
families PKDF291 and DEM4395 and had not been previ-
ously associated with inherited disorders. GTF2F1 encodes
the Rap74 subunit of human general transcription factor
IIF (TFIIF), which is an initiator of transcription and acts
by recruiting RNA polymerase II to the initiation013
complex.34 PCP2 encodes Purkinje cell protein 2, which is
expressed exclusively in Purkinje cells and the retina35 and
might have a role in Purkinje cell development or regula-
tion.36 Pcp2-knockout mice have mild cerebellar hypo-
plasia, and null female mice are affected by anxiety.37,38
Evidence that the CLPP mutation is entirely responsible
for the severe phenotype of family PDF1 can be drawn
from other genes associated with spastic paraplegia. Reces-
sive mutations in SPG7 cause spastic paraplegia.39 SPG7
encodes paraplegin, which, like CLPP, is part of an ATP-
dependent proteolytic complex that degrades misfolded
proteins and regulates ribosome assembly in the mito-
chondrial inner membrane.40 In addition, expression
profiling of lymphocytes and fibroblasts from an indi-
vidual with dominant spastic paraplegia type 13 (SPG13)
due to a mutation in HSPD1, encoding a mitochondrial
heat-shock protein, revealed that this individual had lower
levels of CLPP message and protein than did controls.41
Furthermore, homozygous mutations in AFG3L2, which
forms a heterooligomeric complex with paraplegin, cause
an early-onset spastic-ataxia-neuropathy phenotype.42 It
is thus possible that accumulation of misfolded proteins,
but not those degraded by dysfunctional CLPP, is consis-
tent with progressive spastic paraplegia. It is notable that
this phenotype is only present in the individuals with
the p.Thr145Pro missense variant, which by protein
modeling is predicted to have a more significant effect
on CLPP function. Sanger sequencing of the coding exons
of CLPP in 20 individuals with spastic paraplegia consis-
tent with autosomal-recessive inheritance and no muta-
tion in known spastic paraplegia genes43 identified no
pathogenic mutations (data not shown). This is not
surprising given the significant genetic heterogeneity asso-
ciated with spastic paraplegia.
Severe to profound prelingual SNHL was observed in all
affected individuals of the three families reported here. The
severity of hearing loss in the individuals with CLPPmuta-
tions contrasts with that described in individuals with Per-
rault syndrome due to HARS2 mutations or to HSD17B4
mutations. In the individuals with HARS2 mutations, the
SNHL was progressive in all five affected siblings but varied
strikingly in age of onset and severity;9 in the individuals
with HSD17B4 mutations, there was variable severe
progressive SNHL.8 The profound hearing loss in our cases
with CLPP mutations might reflect an ascertainment bias
in that severely affected individuals are more likely to be
brought to the attention of clinicians. It is possible that
other alleles of CLPP might contribute to milder degrees
of hearing loss. Mutations in CLPP might be relevant to
nonsyndromic hearing loss in males because in the
absence of an affected female sibling, the diagnosis of Per-
rault syndrome would not be considered. The infertility
associated with Perrault syndromemight be either primary
or secondary.8,9 Therefore, there might be hearing-loss-
affected females for whom a diagnosis of Perrault
syndrome has not been suspected because they have had
temporarily normal menstrual cycles.The AmThe previous identification of HARS2 mutations indi-
cated the role of mitochondrial dysfunction in the patho-
genesis of some forms of Perrault syndrome.9 HARS2
encodes mitochondrial histidyl-tRNA synthetase, which
catalyzes the covalent linkage of histidine to its cognate
tRNA and is required in the mitochondria for protein
translation. CLPP is required for protein degradation in
the mitochondria, which also indicates an important role
for mitochondrial protein homeostasis in disease patho-
genesis. Genes encoding other members of interlinking
pathways (Figure S4)44 involved in the mitochondrial
unfolded-protein response (UPRmt) are attractive candi-
dates for other as-yet-undefined causes of Perrault
syndrome.Supplemental Data
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